The Biology of <Emphasis Type="Italic">K-Ras</Emphasis> and <Emphasis Type="Italic">B-Raf</Emphasis> Mutations in Colorectal Cancer |
| |
Authors: | Yixing Jiang Heath Mackley Hua Cheng Jaffer A Ajani |
| |
Institution: | 1.Penn State Hershey Cancer Institute,Penn State College of Medicine,Hershey,USA;2.Department of Gastrointestinal Medical Oncology,The University of Texas M.D. Anderson Cancer Center,Houston,USA |
| |
Abstract: | Ras and Raf proteins are two major players in the MAP kinase pathway. They are crucial downstream regulators of multiple receptor
tyrosine kinase-mediated cell growth, transformation, and maintenance of the malignant phenotype in human cancers. Mutations
have been identified in K-Ras and B-Raf in patients with colorectal cancer. Clinical studies in colorectal cancers demonstrate that the therapeutic efficacy of cetuximab,
a chimeric monoclonal antibody against epidermal growth factor receptor, depends on the presence of wild-type K-Ras. However, mutations in B-Raf do not predict cetuximab resistance. These observations have led to the use of K-Ras as a predictive biomarker, allowing clinicians to direct the therapy of cancer patients based on their K-Ras mutational status. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|